文献速递消化道肿瘤与早癌消化内镜

参加有组织粪便免疫化学检测筛查项目对结直肠癌风险的影响:一项观察性队列研究

Effects of Attendance to an Organized Fecal Immunochemical Test Screening Program on the Risk of Colorectal Cancer: An Observational Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-07

该观察性队列研究比较了意大利某地区两年一次粪便免疫化学检测(FIT)筛查项目的参加者与非参加者的结直肠癌发病率和死亡率。结果显示,参加FIT筛查与男性结直肠癌发病率降低33%、女性降低21%相关,结直肠癌死亡率男性降低65%、女性降低54%。

要点

  • 参加FIT筛查与男性结直肠癌发病率降低33%、女性降低21%相关。
  • 参加FIT筛查与男性结直肠癌死亡率降低65%、女性降低54%相关。
  • 参加者Ⅰ期结直肠癌发病率高于非参加者,而Ⅱ、Ⅲ、Ⅳ期发病率低于非参加者。

核心结论

  • 参加FIT筛查项目与男性结直肠癌发病率降低33%、女性降低21%相关,与男性结直肠癌死亡率降低65%、女性降低54%相关。

研究设计与样本

  • 观察性队列研究,比较意大利某地区两年一次FIT筛查项目参加者与非参加者的结直肠癌发病率和死亡率。
  • 项目始于2005年,目标人群为50至69岁超过1,000,000人。
  • FIT采用单样本OC-Sensor(Eiken Chemical Co,东京,日本), cutoff为≥20 μg血红蛋白/g粪便。
  • 平均年度邀请应答率为51.4%。
  • 参加者为对前2次邀请或不合格前单次邀请做出应答者;非参加者为对任何邀请均未应答者。

主要发现

  • 队列产生2,622,131人年男性风险和2,887,845人年女性风险,分别发生4490例和3309例结直肠癌。
  • 参加者结直肠癌发病率比(IRR)男性为0.65(95% CI,0.61-0.69),女性为0.75(95% CI,0.70-0.80),两性合计为0.69(95% CI,0.66-0.72)。
  • 自选择调整后IRR男性为0.67(95% CI,0.62-0.72),女性为0.79(95% CI,0.72-0.88)。
  • 男性Ⅰ、Ⅱ、Ⅲ、Ⅳ期结直肠癌IRR分别为1.35(95% CI,1.20-1.50)、0.61(95% CI,0.53-0.69)、0.60(95% CI,0.53-0.68)、0.28(95% CI,0.24-0.32);女性分别为1.64(95% CI,1.43-1.89)、0.60(95% CI,0.52-0.69)、0.73(95% CI,0.63-0.85)、0.35(95% CI,0.30-0.42)。
  • 基于发病率的结直肠癌总死亡率比(MRR)男性为0.32(95% CI,0.28-0.37),女性为0.40(95% CI,0.34-0.47),两性合计为0.35(95% CI,0.31-0.39);调整后MRR男性为0.35(95% CI,0.29-0.41),女性为0.46(95% CI,0.37-0.58)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: This cohort study compared colorectal cancer (CRC) incidence and mortality between people who participated in an Italian regional biennial fecal immunochemical test (FIT) screening program and people who did not. METHODS: The program started in 2005. The target population included over 1,000,000 people aged 50 to 69 years. The FIT was a one-sample OC-Sensor (Eiken Chemical Co, Tokyo, Japan) (cutoff, ≥20 μg hemoglobin/g feces). The average annual response rate to invitation was 51.4%. The records of people invited up to June 2016 were extracted from the screening data warehouse. Attenders were subjects who responded to the first 2 invitations or to the single invitation sent them before they became ineligible. Non-attenders were subjects who did not respond to any of these invitations. The records were linked with the regional CRC registry. People registered up to December 2016 were identified. Self-selection-adjusted incidence rate ratios (IRRs) and incidence-based CRC mortality rate ratios (MRRs) for attenders to non-attenders, with 95% confidence intervals (CIs), were calculated. RESULTS: The cohort generated 2,622,131 man-years and 2,887,845 woman-years at risk with 4490 and 3309 CRC cases, respectively. The cohort of attenders was associated with an IRR of 0.65 (95% CI, 0.61-0.69) for men, 0.75 (95% CI, 0.70-0.80) for women and 0.69 (95% CI, 0.66-0.72) for both sexes combined. The self-selection-adjusted IRR was 0.67 (95% CI, 0.62-0.72) for men and 0.79 (95% CI, 0.72-0.88) for women. The IRR for stage I, II, III, and IV CRC was 1.35 (95% CI, 1.20-1.50), 0.61 (95% CI, 0.53-0.69), 0.60 (95% CI, 0.53-0.68) and 0.28 (95% CI, 0.24-0.32) for men and 1.64 (95% CI, 1.43-1.89), 0.60 (95% CI, 0.52-0.69), 0.73 (95% CI, 0.63-0.85) and 0.35 (95% CI, 0.30-0.42) for women. The overall incidence-based CRC MRR was 0.32 (95% CI, 0.28-0.37) for men, 0.40 (95% CI, 0.34-0.47) for women and 0.35 (95% CI, 0.31-0.39) for both sexes combined. The adjusted MRR was 0.35 (95% CI, 0.29-0.41) for men and 0.46 (95% CI, 0.37-0.58) for women. CONCLUSIONS: Attendance to a FIT screening program is associated with a CRC incidence reduction of 33% among men and 21% among women, and a CRC mortality reduction of 65% and 54%, respectively.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Baldacchini F, Bucchi L, Giuliani O, et al. Effects of Attendance to an Organized Fecal Immunochemical Test Screening Program on the Risk of Colorectal Cancer: An Observational Cohort Study. Clin Gastroenterol Hepatol. 2022. PMID: 35144023. doi:10.1016/j.cgh.2022.01.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。